Baker BROS. Advisors LP Buys 1,000,000 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Baker BROS. Advisors LP grew its stake in Replimune Group, Inc. (NASDAQ:REPL) by 10.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 11,045,336 shares of the company’s stock after buying an additional 1,000,000 shares during the quarter. Replimune Group accounts for 1.3% of Baker BROS. Advisors LP’s holdings, making the stock its 12th biggest position. Baker BROS. Advisors LP owned approximately 0.16% of Replimune Group worth $121,057,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Millennium Management LLC boosted its stake in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after purchasing an additional 2,656,173 shares during the period. Braidwell LP lifted its holdings in shares of Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after purchasing an additional 2,057,460 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Replimune Group by 1.2% during the first quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock worth $22,634,000 after buying an additional 32,555 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Replimune Group by 12.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock worth $5,313,000 after buying an additional 52,498 shares in the last quarter. Finally, TD Asset Management Inc raised its position in Replimune Group by 4.6% in the 2nd quarter. TD Asset Management Inc now owns 249,940 shares of the company’s stock valued at $2,249,000 after buying an additional 11,094 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on REPL. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research note on Friday, November 22nd. BMO Capital Markets raised their target price on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Roth Mkm started coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price objective for the company. Finally, Roth Capital raised Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $17.00.

Replimune Group Stock Performance

Shares of REPL stock opened at $14.08 on Monday. The company has a fifty day moving average price of $11.89 and a two-hundred day moving average price of $10.02. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The stock has a market cap of $963.35 million, a P/E ratio of -4.62 and a beta of 1.19. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. As a group, equities analysts predict that Replimune Group, Inc. will post -2.99 EPS for the current year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at $1,184,560.30. The trade was a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 8.80% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.